IOVANCE BIOTHERAPEUTICS, INC. Operating Lease, Payments in USD from Q3 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Iovance Biotherapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q3 2018 to Q3 2025.
  • Iovance Biotherapeutics, Inc. Operating Lease, Payments for the quarter ending September 30, 2025 was $3.42M, a 24% decline year-over-year.
  • Iovance Biotherapeutics, Inc. Operating Lease, Payments for the twelve months ending September 30, 2025 was $16.3M, a 5.59% decline year-over-year.
  • Iovance Biotherapeutics, Inc. annual Operating Lease, Payments for 2024 was $18.1M, a 7.4% increase from 2023.
  • Iovance Biotherapeutics, Inc. annual Operating Lease, Payments for 2023 was $16.9M, a 18.7% increase from 2022.
  • Iovance Biotherapeutics, Inc. annual Operating Lease, Payments for 2022 was $14.2M, a 15.4% increase from 2021.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)

IOVANCE BIOTHERAPEUTICS, INC. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $16.3M $3.42M -$1.08M -24% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $17.4M $3.62M -$671K -15.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $18M $4.21M -$80K -1.87% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $18.1M $5.04M +$867K +20.8% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $17.3M $4.5M +$197K +4.57% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $17.1M $4.29M +$56K +1.32% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $17M $4.29M +$129K +3.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $16.9M $4.17M +$220K +5.57% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $16.7M $4.31M +$1.12M +35.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $15.5M $4.24M +$973K +29.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $14.6M $4.16M +$350K +9.18% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $14.2M $3.95M +$215K +5.76% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $14M $3.19M -$417K -11.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $14.4M $3.26M +$750K +29.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $13.7M $3.81M +$1.35M +54.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $12.3M $3.73M +$1.36M +57.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $11M $3.61M +$1.71M +90.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $9.25M $2.51M +$606K +31.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $8.64M $2.47M +$269K +12.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $8.37M $2.38M -$406K -14.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $8.78M $1.89M -$570K -23.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $9.35M $1.91M -$71K -3.59% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $9.42M $2.2M +$797K +56.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $8.62M $2.78M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $2.46M +$2.4M +4075% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.98M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $1.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q3 2018 $59K Sep 26, 2018 Oct 19, 2018 10-Q 2020-05-05

IOVANCE BIOTHERAPEUTICS, INC. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $18.1M +$1.25M +7.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $16.9M +$2.66M +18.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $14.2M +$1.89M +15.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $12.3M +$3.94M +47.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-28
2020 $8.37M -$250K -2.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
2019 $8.62M Jan 1, 2019 Dec 31, 2019 10-K 2021-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.